Medical Use of Functionalized Chitosan
案件概要
出願人
MEXBRAIN; UNIVERSITE CLAUDE BERNARD LYON 1; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE JEAN MONNET SAINT-ETIENNE; INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON
発明者
Coralie Grange; Axel Aigle; Thomas Brichart; Olivier Tillement; François Lux; Laurent David; Victor Ehrlich; Thomas Grea; Juan Salazar Ariza
IPC分類
CPC分類
The present disclosure relates to a functionalized statistic chitosan of weight average molecular mass between 100 kDa and 1000 kDa and of formula (I): wherein each Rc is independently a moiety comprising a chelating agent, each Z is independently a linker which is a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said hydrocarbon chain is linear or branched and optionally contains one or more unsaturations and one or more heteroatoms, x is between 0.005 and 0.7, preferably between 0.05 and 0.7, y is between 0.01 and 0.7, preferably between 0.05 and 0.2, the ratio y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, and the sum x+y being greater than or equal to 0.15, for use in the treatment of diseases characterized by local inflammation induced by and/or inducing a deregulation of metal homeostasis and increased oxidative stress, in a subject in need thereof.
原文(中国語)
The present disclosure relates to a functionalized statistic chitosan of weight average molecular mass between 100 kDa and 1000 kDa and of formula (I): wherein each Rc is independently a moiety comprising a chelating agent, each Z is independently a linker which is a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said hydrocarbon chain is linear or branched and optionally contains one or more unsaturations and one or more heteroatoms, x is between 0.005 and 0.7, preferably between 0.05 and 0.7, y is between 0.01 and 0.7, preferably between 0.05 and 0.2, the ratio y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, and the sum x+y being greater than or equal to 0.15, for use in the treatment of diseases characterized by local inflammation induced by and/or inducing a deregulation of metal homeostasis and increased oxidative stress, in a subject in need thereof.
外部リソース